Aurobindo Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 1265.85, down 4.65% on the day as on 12:59 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 24233.2. The Sensex is at 79752.86, up 0.34%.Aurobindo Pharma Ltd has eased around 15% in last one month.Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has eased around 5.71% in last one month and is currently quoting at 22542.25, down 0.95% on the day. The volume in the stock stood at 23.08 lakh shares today, compared to the daily average of 8.02 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1269.35, down 4.92% on the day. Aurobindo Pharma Ltd jumped 29.25% in last one year as compared to a 24.11% rally in NIFTY and a 43.47% spurt in the Nifty Pharma index.The PE of the stock is 40.7 based on TTM earnings ending June 24.Powered by Capital Market - Live

Net profit of Aurobindo Pharma rose 7.95% to Rs 817.38 crore in the quarter ended September 2024 as against Rs 757.18 crore during the previous quarter ended September 2023. Sales rose 6.93% to Rs 7646.21 crore in the quarter ended September 2024 as against Rs 7150.71 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales7646.217150.71 7 OPM %20.4819.21 - PBDT1589.741493.14 6 PBT1207.461075.64 12 NP817.38757.18 8 Powered by Capital Market - Live

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

Aurobindo Pharma has completed the acquisition of balance 49% stake in its subsidiary, GLS Pharma on 25 October 2024. With this transaction, GLS Pharma has become a wholly owned subsidiary of the Company.Powered by Capital Market - Live

Aurobindo Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 1509.05, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 25134.8. The Sensex is at 82005.72, up 0.45%. Aurobindo Pharma Ltd has slipped around 0.62% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has slipped around 2.13% in last one month and is currently quoting at 23307.95, up 1.91% on the day. The volume in the stock stood at 3.63 lakh shares today, compared to the daily average of 13.57 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1519, up 1.41% on the day. Aurobindo Pharma Ltd is up 67.5% in last one year as compared to a 27.65% spurt in NIFTY and a 57.23% spurt in the Nifty Pharma index.The PE of the stock is 45.69 based on TTM earnings ending June 24.Powered by Capital Market - Live

Aurogen South Africa (Aurogen), a wholly owned step-down subsidiary of Aurobindo Pharma in South Africa, has entered into an agreement with Novabee Proprietary, to sell and dispose of the entire 50% shares held by Aurogen in Novagen. After the disposal of 50% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen.Powered by Capital Market - Live

Aurogen South Africa, (Aurogen) a wholly owned step-down subsidiary of Aurobindo Pharma in South Africa, has entered into an agreement with Rene Glyne Family trust to sell and dispose of the entire 24.5% shares held by Aurogen. After the disposal of 24.5% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen BBBEE Invest Co (Proprietary). Powered by Capital Market - Live

The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Keflet Tablets, 250 mg and 500 mg, of Eli Lilly and company. The product will be launched in Q3FY25. Aurobindo Pharma was granted Competitive Generic Therapy (CGT) designation for Cephalexin Tablets USP, 250 mg and 500 mg, and is eligible for 180 days of shared generic drug exclusivity. Cephalexin Tablets USP, 250 mg and 500 mg are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms. The drug maker now has a total of 523 ANDA approvals (506 Final approvals and 17 tentative approvals) from USFDA. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 79.5% jump in consolidated net profit to Rs 908.75 crore on a 17.1% rise in revenue from operations to Rs 7,580.15 crore in Q4 FY24 over Q4 FY23. Shares of Aurobindo Pharma rose 0.83% to Rs 1,450.55 on the BSE. Powered by Capital Market - Live

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cephalexin Tablets USP, 250 mg and 500 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Keflet Tablets, 250 mg and 500 mg, of Eli Lilly and Company. Aurobindo Pharma was granted Competitive Generic Therapy (CGT) designation for Cephalexin Tablets USP, 250 mg and 500 mg, and is eligible for 180 days of shared generic drug exclusivity. The product is expected to be launched in Q3FY25. Cephalexin Tablets USP, 250 mg and 500 mg are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms. Powered by Capital Market - Live

The USFDA conducted inspection from 23 September to 27 September 2024.The inspection was closed with 10 observations. The firm stated that the observations are of procedural in nature and will be responded to within the stipulated time. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 61.1% surge in consolidated net profit to Rs 919.22 crore on a 9.8% rise in revenue from operations to Rs 7,457.65 crore in Q1 FY25 over Q1 FY24.Powered by Capital Market - Live